Full Press Release Details
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting.
Oral Presentations:Encaleret Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE TrialPresenter:Filomena Cetani, M.D., Ph.D., University of Pisa, ITDate & Time:Tuesday, May 12 at 11:50 am CEST
Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-FunctionCASRVariants as the Most Common Genetic Cause IdentifiedPresenter:Arun Mathew, BridgeBio Endocrinology, U.S.Date & Time:Tuesday, May 12 at 12:20 pm CEST
Poster:Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Quality of Life Measures in Adult Participants in the CLARIFY Disease Monitoring StudyPresenter:Heide Siggelkow, M.D., University Medical Center of Göttingen, DEPoster ID:P72Date & Time:Sunday, May 10 at 4:55 pm CEST and Monday, May 11 at 5 pm CEST
ePoster:Epidemiology and Clinical Management of ADH1: A Systematic Literature ReviewPresenter:Arun Mathew, BridgeBio Endocrinology, U.S.Poster ID:EP260
About BridgeBioBridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visitbridgebio.comand follow us onLinkedIn,X,Facebook,Instagram,YouTube, andTikTok.